By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CSL Behring 

1020 First Avenue
P.O. Box 61501
King of Prussia  Pennsylvania  19406-0901  U.S.A.
Phone: 610-878-4000 Fax: 610-878-4009



Company News
Centers For Medicare And Medicaid Services Extends New Technology Add-On Payment For CSL Behring’s Kcentra For Third Year 9/8/2015 11:33:04 AM
CSL Behring Enrolls First Patient In Global Phase II/III Study Of rVIIa-FP For On-Demand Treatment Of Patients With Hemophilia A Or B With Inhibitors 8/25/2015 7:51:12 AM
Swissmedic Accepts For Review CSL Behring's MAA For rIX-FP For Patients With Hemophilia B 7/28/2015 11:23:36 AM
U.S. FDA Accepts For Review CSL Behring's Biologics License Application For Its Novel Rviii-Singlechain Therapy For Patients With Hemophilia A 7/28/2015 11:21:01 AM
CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient 6/29/2015 12:44:55 PM
CSL Behring Receives Positive CHMP Opinion For Respreeza (Human Alpha-1 Proteinase Inhibitor) As Maintenance Treatment For Patients With Severe Alpha-1 Antitrypsin Deficiency In Europe 6/29/2015 12:25:55 PM
CSL Behring Presents rIX-FP For Hemophilia B Phase III Data Evaluating Efficacy, Safety And Improved Dosing At ISTH 2015 6/25/2015 6:18:30 AM
CSL Behring Announces Pivotal Data Of Novel rVIII-SingleChain Therapy In Adolescents And Adults With Hemophilia A 6/24/2015 7:13:10 AM
CSL Behring To Present Pivotal Data For rVIII-SingleChain And rIX-FP At 2015 ISTH Congress 6/16/2015 11:05:21 AM
CSL Behring Release: Important New Findings Published In The Lancet Support The Use Of Zemaira [Alpha1-Proteinase Inhibitor (Human)] In Patients With Alpha-1 Antitrypsin Deficiency (AATD) 6/1/2015 7:46:39 AM